Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1A1 | P14550 | 14/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 14/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23998619 | 0.76 | AKR1A1 (0.79) | AKR1A1AKR1B1ITGA4GAACRHBP | |
| SCHEMBL21844099 | 0.74 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4CRHBPCRHR2 | |
| SCHEMBL21095653 | 0.74 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4CRHBPCRHR2 | |
| SCHEMBL21844141 | 0.74 | AKR1A1 (1.00) | AKR1A1AKR1B1ITGA4CRHBPCRHR2 | |
| SCHEMBL20845782 | 0.73 | AKR1B1 (0.69) | AKR1A1AKR1B1ITGA4PDK2 | |
| SCHEMBL23998450 | 0.72 | AKR1A1 (0.90) | AKR1A1AKR1B1ITGA4CRHBPCRHR2 | |
| SCHEMBL26232338 | 0.72 | AKR1A1 (0.68) | AKR1A1AKR1B1ITGA4GAACRHBP | |
| SCHEMBL23998454 | 0.72 | AKR1A1 (0.71) | AKR1A1AKR1B1ITGA4CRHBPCRHR2 | |
| SCHEMBL21844217 | 0.72 | AKR1B1 (0.79) | AKR1A1AKR1B1ITGA4CRHBPCRHR2 | |
| SCHEMBL21844348 | 0.71 | AKR1A1 (0.88) | AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | UNIV CASE WESTERN RESERVE (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | PCSK9, HMGCR, PCSK7 | AKR1A1 8/4885AKR1B1 9/4885ITGA4 4832/4885 |
| US-20190183861-A1 | COMPOSITIONS AND METHODS OF MODULATING S-NITROSYLATION | AKR1B1, AKR1C2, AKR1A1 | AKR1A1 3/4885AKR1B1 1/4885ITGA4 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.